CV Sciences Inc (OTCMKTS:CVSI) demonstrated the health benefits of PlusCBD products in a two-year trial conducted on millions of customers. The health benefits and safety details of these health supplements are published in the Dietary Supplements Journal.
Hemp-based Cannabidiol as a dietary supplement
The two-year study demonstrates hemp-derived cannabidiol (CBD) as an excellent dietary supplement without any noticeable side effects in several million users. According to the study, it is well-tolerated and safe to use. People, who used even higher dosages of PlusCBD products, have not reported any liver toxicity over a two-year study.
Co-founder of SSS (Supplement Safety Solutions) and a leading author, Stephen Schmitz said it is the first time that CBD dietary supplement is used in the real world conditions without any noticeable safety issues. The data is collected over two years for actual users and finds that it is safe to use.
Improves HDL cholesterol
According to Hector L. Lopez, a lead author, people, who consumed PLusCBD products, improved HDL cholesterol significantly than placebo. Response to stress, sound sleep, and wellness, and life pleasure are considerably improved among the participants, who took PlusCBD products. Lopez said the PlusCBD products demonstrated an excellent safety profile. The group, who are administered these products, have not shown any side effects on the liver. The senior vice president (Clinical/ Regulatory affairs) of CV Sciences, Duffy MacKay, stated the studies supported the health benefits and safety of hemp-based CBD products.
Q1 earnings in 2020
CV Sciences posted $8.3 million in revenues in Q1 2020. Its e-commerce sales jumped by 15% compared to the same period last year and accounted for 24% of the overall revenues.
In January 2020, CV Sciences introduced +PlusCBD oil updated website to improve the navigation experience for users and boost online sales. The USPTO awarded notice of allowance for CV Sciences proprietary nicotine and cannabidiol formulation to cure addiction to smokeless tobacco.
Despite the impact of ongoing coronavirus and challenging market conditions, CV Sciences posted excellent revenues in Q1 2020 and provided guidance. The company reorganized its operations to mitigate the impact of the global health hazards created by COVID-19 and improve performance. CEO, Joseph Dowling said the company is operating its distribution and production facilities to deliver high-quality CBD products derived from hemp to satisfy the growing demand.
Post Views: 33,912 Can you spot the difference between the hemp plant and marijuana plant? Hint: It’s not in the...
Stem Holdings Inc (OTCMKTS:STMH) Reports A Growth Of 960% In Q3 2020: Unveils TJGardens Branded Tinctures
Post Views: 774 Stem Holdings Inc (OTCMKTS:STMH) posted an increase of 960% YoY to $6.7 million in Q3 2020. It...
Indiva Ltd (OTCMKTS:NDVAF) Signs Three Provincial Agreements: Expands Distribution Network To Eight Provinces: Reports A Robust Growth Of 1273.7% In Q2 2020 Revenues
Post Views: 694 Indiva Ltd (OTCMKTS:NDVAF) posted a robust growth of 1273.7% YoY to CAD 2.826 million in revenues in...
4Front Ventures Corp (OTCMKTS:FFNTF) Receives Approval From CCC For Mission Dispensary and Cultivation Facilities In Worcester: Will Commence Adult-Use Cannabis Sales
Post Views: 743 CCC (Cannabis Control Commission) in Massachusetts approved cultivation and processing facilities and Mission Dispensary of 4Front Ventures...
Pure Sunfarms, A Joint Venture Of Village Farms International Inc (NASDAQ:VFF), Ships Bottled Oil Products TO British Columbia
Post Views: 821 Pure Sunfarms, which is a Village Farms International Inc (NASDAQ:VFF) JV, commenced shipment of Cannabis 2.0 products...
Health Canada Grants Cannabis 2.0 License To Abba Medix Corp, An Auxiliary Of Canada House Cannabis Group Inc (OTCMKTS:SARSF)
Post Views: 671 Abba Medix Corp., a wholly-owned subsidiary of Canada House Cannabis Group Inc (OTCMKTS:SARSF), received an amended cannabis...